Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tocilizumab: A Therapeutic Cache Against the Treatment of Severe Cases of COVID-19

NCT04560205 is registered in ClinicalTrials.gov with Lahore General Hospital as lead sponsor.

NCT NCT04560205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04560205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tocilizumab: A Therapeutic Cache Against the Treatment of Severe Cases of COVID-19
Lead sponsor
Lahore General Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
May 1, 2020
Completion date
December 30, 2020
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov infection